Advanced Cancer Therapies in China

Prepared by Regenerative Medicine China · Public sources checked 20 September 2026. Patient information, not an individual medical recommendation.

What question are you trying to answer?

This guide covers advanced cancer cell therapy and therapeutic vaccines in China. These are oncology approaches; they should not be confused with regenerative stem-cell injections or general immune-boosting services.

I have a solid tumour and want to understand NK therapy. Read the NK cell therapy guide and discuss the exact combination regimen with your oncologist.
My tumour has confirmed EBV involvement. Start with the EBV mRNA therapy guide; the tumour diagnosis and relevant test report matter.
I am unsure which approach is relevant. Submit your diagnosis and treatment history for an administrative records check before any formal specialist review.

NK, TIL, DC and mRNA: different approaches

NK cells

Natural killer cells are an immune-cell approach. The Lecheng announcement discussed below concerns an autologous NK technique used alongside immune medicines for solid tumours.

Read NK evidence and access questions →

EBV mRNA

A therapeutic vaccine approach intended to stimulate an immune response against EBV-associated tumour targets. It is not an infusion of expanded NK cells.

Read EBV mRNA evidence and access questions →

TIL

Tumour-infiltrating lymphocytes are T cells collected from a tumour and expanded. The exact product, cancer type and treatment setting matter; an overseas approval does not confirm access in China.

NCI: T-cell transfer therapy

DC vaccines

Dendritic-cell vaccines use antigen-presenting immune cells. Different DC preparations and targets should not be treated as one interchangeable therapy.

NCI: cancer treatment vaccines

TIL and DC are included here for comparison. We have not confirmed a bookable international-patient pathway for them through RMC.

Separate project announcements from treatment evidence

West China Lecheng Hospital has published an announcement about an autologous NK adjunctive technique. West China Hospital has separately reported an EBV-targeted mRNA technique in Lecheng. The linked detail pages distinguish these announcements from trial registrations and patient-specific access.

An announcement establishes what an institution reports. A trial record describes a study. Neither alone proves a survival benefit for your cancer, provides an individual risk estimate or confirms admission. Ask for the underlying clinical publication, comparison group, follow-up period and the protocol relevant to your case.

Hospital review before travel

RMC coordinates information and communication; we do not make treatment decisions. Naming a hospital in a source does not establish a partnership or an appointment channel. Read how we verify institutions and our five-gate verification process.

Confirm the exact product or procedure, hospital, indication and applicable regulatory route.
Ask the institution to confirm current international-patient intake and the documents required for review.
Obtain an individual eligibility decision, written risks and an itemised quotation before paying or travelling.

Records to prepare for an oncology review

Pathology report, cancer type, stage and date of diagnosis.
A dated treatment timeline: surgery, radiotherapy, chemotherapy, targeted medicines and immunotherapy, including response and reasons for stopping.
Recent imaging reports, relevant biomarker results and your oncologist’s summary.
Current medicines, significant illnesses and the question you want a specialist to answer.

Start with a short summary and selected reports. Our form accepts up to 3 PDF/JPEG/PNG files, 5 MB each and 10 MB combined. Do not send passport copies or large imaging archives at this stage. See medical-record preparation.

What should a cancer therapy quotation include?

We have not verified a current, patient-specific international-patient price for these pathways. A per-injection figure is not a complete treatment budget. Ask for separate charges for specialist review, pathology or biomarker tests, cell collection or manufacture where relevant, medicines, administration, admission, adverse-event care and follow-up.

Also clarify cancellation terms if you are ineligible or a product cannot be prepared, which research costs are covered by a sponsor, and which travel, interpreting and accommodation costs are excluded. Do not apply stem-cell cost estimates to an oncology protocol. Clinical-trial participation is not a treatment package.

Plan the China journey after the clinical decision

Keep your treating oncologist involved. Do not delay or stop an existing treatment plan to pursue an unconfirmed option. Before travel, establish the expected visit schedule, need for admission, what happens if treatment is unsuitable, and who will manage complications or follow-up after you return home. See the international patient guide.

Questions patients ask

Which advanced cancer therapy is best?

There is no single best option across cancers. Pathology, stage, biomarkers, prior treatment and the exact evidence determine what a qualified oncology team may consider.

Can RMC guarantee hospital acceptance?

No. A records submission is an administrative first step. Only the institution can confirm eligibility and current access.

Is mRNA therapy the same as cell therapy?

No. An mRNA therapeutic vaccine provides genetic instructions intended to stimulate an immune response; it is different from giving expanded immune cells.

Sources and verification limits

Primary institutional and registry sources are linked above. We have not independently confirmed international-patient intake, a current quotation or an RMC partnership with the named institutions. Public-source checking is not clinical peer review.